Simply Wall St.8d agobearish
ImmunityBio FDA Warning And Lawsuits Test Anktiva Growth StoryImmunityBio received an FDA warning letter criticizing promotional claims for its lead product Anktiva. Following the warning letter, multiple class action lawsuits were filed alleging misleading statements and securities fraud. The issues center on whether the company accurately represented Anktiva's profile in marketing and investor communications. For investors tracking ImmunityBio (NasdaqGS:IBRX), this comes at a time when interest in the stock has been high, with a current share price...